Mavyret — Medical Mutual
Chronic Hepatitis C Virus (HCV), Genotype 3, Treatment-Experienced
Initial criteria
- Patient age ≥ 3 years
- No cirrhosis or compensated cirrhosis (Child-Pugh A)
- Relapse/partial/null with PegIFN/IFN with ribavirin or Sovaldi-based regimen
- Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Approval duration
16 weeks